Ye Qiu1, Zongxin Zhang1, Ying Chen1. 1. Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, China.
Abstract
BACKGROUND: Previous studies have investigated the role of systemic immune-inflammation index (SII) as a prognostic factor for gastric cancer (GC) patients, although with inconsistent results. Thus, the aim of this study was to identify the prognostic value of SII in GC through meta-analysis. METHODS: We systematically searched the PubMed, Embase, and Web of Science databases for relevant studies investigating the prognostic role of SII in GC up to December 2019. The hazard ratios (HRs) and 95% confidence intervals (CIs) related to overall survival (OS) and disease-free survival (DFS) were combined. Odds ratios (ORs) and 95% CIs were pooled to assess the correlation between SII and clinicopathological features of GC. RESULTS: A total of eight studies, comprising 4,236 patients, were included in this meta-analysis. Pooled analysis indicated that a high pretreatment SII predicted poor OS (HR=1.40, 95% CI=1.08-1.81, p=0.010) but not poor DFS (HR=1.30, 95% CI=0.92-1.83, p=0.140) in GC. In addition, an elevated SII correlated with an advanced tumor-node-metastasis stage (OR=2.34, 95% CI=1.40-3.92, p=0.001), T3-T4 stage (OR=2.25, 95% CI=1.34-3.77, p=0.002), positive lymph node metastasis (OR=1.79, 95% CI=1.12-2.87, p=0.016), and tumor size ≥ 5 cm (OR=2.28, 95% CI=1.62-3.22, p<0.001) in patients with GC. CONCLUSIONS: A high pretreatment SII significantly associated with poorer survival outcomes as well as several clinical characteristics in GC. We suggest that SII could be monitored to guide prognostication and provide reliable information on the risk of disease progression in GC.
BACKGROUND: Previous studies have investigated the role of systemic immune-inflammation index (SII) as a prognostic factor for gastric cancer (GC) patients, although with inconsistent results. Thus, the aim of this study was to identify the prognostic value of SII in GC through meta-analysis. METHODS: We systematically searched the PubMed, Embase, and Web of Science databases for relevant studies investigating the prognostic role of SII in GC up to December 2019. The hazard ratios (HRs) and 95% confidence intervals (CIs) related to overall survival (OS) and disease-free survival (DFS) were combined. Odds ratios (ORs) and 95% CIs were pooled to assess the correlation between SII and clinicopathological features of GC. RESULTS: A total of eight studies, comprising 4,236 patients, were included in this meta-analysis. Pooled analysis indicated that a high pretreatment SII predicted poor OS (HR=1.40, 95% CI=1.08-1.81, p=0.010) but not poor DFS (HR=1.30, 95% CI=0.92-1.83, p=0.140) in GC. In addition, an elevated SII correlated with an advanced tumor-node-metastasis stage (OR=2.34, 95% CI=1.40-3.92, p=0.001), T3-T4 stage (OR=2.25, 95% CI=1.34-3.77, p=0.002), positive lymph node metastasis (OR=1.79, 95% CI=1.12-2.87, p=0.016), and tumor size ≥ 5 cm (OR=2.28, 95% CI=1.62-3.22, p<0.001) in patients with GC. CONCLUSIONS: A high pretreatment SII significantly associated with poorer survival outcomes as well as several clinical characteristics in GC. We suggest that SII could be monitored to guide prognostication and provide reliable information on the risk of disease progression in GC.
Authors: Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Joseph Chao; Prajnan Das; Crystal S Denlinger; Paul Fanta; Farhood Farjah; Charles S Fuchs; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; Catherine Linn; A Craig Lockhart; Quan P Ly; Mary F Mulcahy; Mark B Orringer; Kyle A Perry; George A Poultsides; Walter J Scott; Vivian E Strong; Mary Kay Washington; Benny Weksler; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2016-10 Impact factor: 11.908
Authors: Nikolaos Charalampakis; Panagiota Economopoulou; Ioannis Kotsantis; Maria Tolia; Dimitrios Schizas; Theodore Liakakos; Elena Elimova; Jaffer A Ajani; Amanda Psyrri Journal: Cancer Med Date: 2017-12-13 Impact factor: 4.452
Authors: Sara Bleve; Maria Concetta Cursano; Chiara Casadei; Giuseppe Schepisi; Cecilia Menna; Milena Urbini; Caterina Gianni; Silvia De Padova; Alessia Filograna; Valentina Gallà; Giovanni Rosti; Domenico Barone; Michal Chovanec; Michal Mego; Ugo De Giorgi Journal: Front Oncol Date: 2022-06-10 Impact factor: 5.738